Showcasing Preclinical Development of Byondis’ Antifolate Linker-Drug ADCs

• Presenting the development of a novel antifolate linker-drug platform, a toxin class with a clinically validated mechanism of action
• Discussing preclinical development of antifolate-based ADCs across in vitro and in vivo studies
• Outlining antifolate payload mechanism of action and physicochemical properties

Speakers:

Renier Heijkants

Lead Scientist

Byondis